An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York Metropolis on Dec. 11, 2023.
Brendan Mcdermid | Reuters
Eli Lilly‘s weight-loss drug Zepbound showed promise as a medication for sleep apnea — giving investors more confidence to take care of proudly owning the realm’s most necessary properly being-care company even after or no longer it has been crushing the S&P 500’s efficiency all by scheme of the last three years.
